Diagnostic Center | April 05, 2024
Merck initiates Phase 3 clinical trial of investigational oral KRAS G12C inhibitor MK-1084
For the first-line treatment of certain patients with metastatic non-small cell lung cancer
For the first-line treatment of certain patients with metastatic non-small cell lung cancer
Company reaffirms commitment to reduce the global burden of HPV-related diseases, including certain cancers
Investigational cell therapy bemdaneprocel continues to be well tolerated with no major safety issues in all 12 participants in low and high dose cohorts through 18 months
Clinical findings support the safety and efficacy of BMND08 at a maximum dosage of 12mg
MASH is a chronic and progressive liver disease characterised by fat accumulation and inflammation in the liver,
This Phase III clinical trial is a randomized, double-blind, placebo-controlled, multicenter clinical trial in China to evaluate the safety and efficacy of ASC40
Innovent will supply sintilimab for the collaborated clinical trial
Studies have demonstrated that ZYIL1 is highly potent and can suppress inflammation caused by NLRP3 inflammasome activation
LG Chem is making progress in the development of the world's first oral treatment for rare forms of obesity.
Seamless transition from preclinical to first-in-human trials with EUDRACAP platform technology
Subscribe To Our Newsletter & Stay Updated
